One last time: does anyone else think that Novo Nordisk is finally truly undervalued?
u/Civil-Community-1367 ·
Reddit — r/ValueInvesting
· April 09, 2026 at 07:32
· ⬆ 17 pts
· 💬 24 comments
| View on Reddit ↗
AI Summary
Summary
Post details Novo Nordisk's launch of a higher-dose, more effective weight-loss drug (Wegovy HD), its competitive pricing, and strategic partnerships to expand access.
Author's thesis: These positive developments, coupled with upcoming earnings, may mean the stock is finally "truly undervalued."
Quality assessment: A mix of factual news summary and speculative opinion. Contains specific data points but lacks in-depth financial analysis (e.g., valuation metrics, market sizing). Closer to informed speculation than rigorous DD.
Score17
Comments24
Upvote %78%
▶ Full Post Text
Novo Nordisk launched Wegovy HD (7.2 mg) in the U.S., a 3× increase from the prior 2.4 mg dose, delivering \~20.7–21% weight loss versus \~17–18% previously. The drug is priced at $399/month cash, below Lilly’s $449 Zepbound, with insured patients paying as little as $25/month.
The company also partnered with Hims & Hers and other telehealth platforms to expand access, with GLP-1 offerings starting around $149/month. At the same time, Novo introduced subscription pricing ($249–$329/month) and moved to restrict non-FDA compounded competitors, tightening control over distribution and pricing.
The pill is out now and more people should know about it
The next earnings should be critical on May 5th
Novo launched a superior dose of Wegovy (HD) with better efficacy, at a competitive price point, and expanded access via telehealth partnerships. This strengthens Novo's competitive moat against Eli Lilly and could drive market share growth and revenue upside, potentially not yet reflected in the stock price ahead of critical May 5th earnings. Positive product cycle news and strategic moves create a near-term catalyst for the stock, supporting the author's view of potential undervaluation. Earnings miss on May 5th; stronger-than-expected competitive response from Eli Lilly (LLY); regulatory pushback on pricing or distribution.
This Reddit post, published April 09, 2026,
features u/Civil-Community-1367
discussing NVO.
1 trade idea extracted by AI with direction and confidence scoring.